|Tested species reactivity||Mammal|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Synthetic internal domain of the C-erbB-2 oncoprotein.|
|Storage buffer||tissue culture supernatant|
|Contains||0.1% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunohistochemistry (Frozen) (IHC (F))||1:5-1:10|
|Immunohistochemistry (Paraffin) (IHC (P))||1:5-1:10|
|Western Blot (WB)||Assay dependent.|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Specific binding has been demonstrated by immunoprecipitation with c-erbB-2 oncoprotein from SKBr3 cells. A positive control of breast adenocarcinoma is recommended.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Heat shock protein 27 and gross cystic disease fluid protein 15 play critical roles in molecular apocrine breast cancer.
MA1-35720 was used in immunohistochemistry to characterize human molecular apocrine breast cancer samples
|Liu X,Feng C,Liu J,Zhao L,Liu J,Zhang W,Liu N,Niu Y||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (37:8027)||2016|
PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer.
MA1-35720 was used in immunocytochemistry and western blot to study the interactions between PMCA2 and HER2 in breast cancer cells
|Jeong J,VanHouten JN,Dann P,Kim W,Sullivan C,Yu H,Liotta L,Espina V,Stern DF,Friedman PA,Wysolmerski JJ||Proceedings of the National Academy of Sciences of the United States of America (113:E282)||2016|
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
MA1-35720 was used in immunohistochemistry (paraffin) to study BRAC1-deficiency in sporadic breast cancer.
|Ren J,Jin F,Yu Z,Zhao L,Wang L,Bai X,Zhao H,Yao W,Mi X,Wang E,Olopade OI,Wei M||Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (34:3945)||2013|
An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy.
MA1-35720 was used in immunohistochemistry (paraffin) to study triple negative breast cancer in Chinese women.
|Zhang J,Wang Y,Yin Q,Zhang W,Zhang T,Niu Y||International journal of clinical and experimental pathology (6:1380)||2013|
Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.
MA1-35720 was used in immunohistochemistry (paraffin) to investigate prognostic or predictive biomarkers of breast cancer.
|Pereira CB,Leal MF,de Souza CR,Montenegro RC,Rey JA,Carvalho AA,Assumpção PP,Khayat AS,Pinto GR,Demachki S,de Arruda Cardoso Smith M,Burbano RR||PloS one (8:null)||2013|
Fine-needle aspiration cytology findings of an uncommon micropapillary variant of pure mucinous carcinoma of the breast: review of patients over an 8-year period.
MA1-35720 was used in immunohistochemistry (paraffin) to discuss features used to classify pure mucinous carcinomas of the breast.
|Ng WK||Cancer (96:280)||2002|
Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes.
MA1-35720 was used in western blot to evaluate the role of leptin/STAT3 and HER2 receptor in tamoxifen resistance
|Papanikolaou V,Stefanou N,Dubos S,Papathanasiou I,Palianopoulou M,Valiakou V,Tsezou A||Cellular oncology (Dordrecht) (38:155)||2015|
Survivin regulation by HER2 through NF-¿B and c-myc in irradiated breast cancer cells.
MA1-35720 was used in western blot to study the importance of survivin to HER2(+) breast cancer radioresistance
|Papanikolaou V,Iliopoulos D,Dimou I,Dubos S,Kappas C,Kitsiou-Tzeli S,Tsezou A||Journal of cellular and molecular medicine (15:1542)||2011|
Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.
MA1-35720 was used in western blot to study the biological, molecular and cellular effects of Herceptin in ovarian carcinoma
|Delord JP,Quideau S,Rochaix P,Caselles O,Couderc B,Hennebelle I,Courbon F,Canal P,Allal BC||British journal of cancer (103:61)||2010|
Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma.
MA1-35720 was used in western blot to investigate the efficacy of trastuzumab in the prevention of relapse of ovarian carcinomas
|Delord JP,Allal C,Canal M,Mery E,Rochaix P,Hennebelle I,Pradines A,Chatelut E,Bugat R,Guichard S,Canal P||Annals of oncology : official journal of the European Society for Medical Oncology (16:1889)||2005|
Contrast enhanced computed tomography is indicative for angiogenesis pattern and display prognostic significance in breast cancer.
MA1-35720 was used in immunohistochemistry - paraffin section to use Contrast-enhanced computer technology to display prognostic significance in breast cancer
|Li J,Zhang Y,Zhang W,Gao Y,Jia S,Guo J||BMC cancer (14:null)||2014|
Assessment of Her-2/neu status using immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology smears: experience from a tertiary care centre in India.
MA1-35720 was used in immunohistochemistry to assess the accuracy of breast cancer HER2 determinations made using immunohistochemical and FISH analysis of fine-needle aspiration cytology smears
|Durgapal P,Mathur SR,Kalamuddin M,Datta Gupta S,Parshad R,Julka PK,Panda SK||Diagnostic cytopathology (42:726)||2014|
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
MA1-35720 was used in immunohistochemistry to attempt to identify prognostic biomarkers in serous ovarian cancer patients treated with neoadjuvant chemotherapy
|Khandakar B,Mathur SR,Kumar L,Kumar S,Datta Gupta S,Iyer VK,Kalaivani M||BioMed research international (2014:null)||2014|
Primary acinic cell carcinoma of the breast: a case report and review of the literature.
MA1-35720 was used in immunohistochemistry to report the case of primary acinic cell carcinoma of the breast in a 38-year-old woman.
|Zhao Y,Li W,Lang R,Yang Y,Gao X,Zheng Y,Zhang C,Fu X,Fu L||International journal of surgical pathology (22:177)||2014|
Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
MA1-35720 was used in immunohistochemistry to study the value of Ki67 expression in predicting the response of breast cancer patients to neoadjuvant chemotherapy
|Kim KI,Lee KH,Kim TR,Chun YS,Lee TH,Park HK||Journal of breast cancer (17:40)||2014|
Are breast cancer molecular classes predictive of survival in patients with long follow-up?
MA1-35720 was used in immunohistochemistry to study the value of breast cancer molecular class in predicting long-term survival
|Pracella D,Bonin S,Barbazza R,Sapino A,Castellano I,Sulfaro S,Stanta G||Disease markers (35:595)||2013|
Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
MA1-35720 was used in immunohistochemistry to study the relationships between tumor-infiltrating lymphocytes, breast cancer characteristics and tumor recurrence
|Kim ST,Jeong H,Woo OH,Seo JH,Kim A,Lee ES,Shin SW,Kim YH,Kim JS,Park KH||American journal of clinical oncology (36:224)||2013|
Plasma human mammaglobin mRNA associated with poor outcome in patients with breast cancer.
MA1-35720 was used in immunohistochemistry to study the prognostic value of plasma mammoglobin mRNA levels in breast cancer
|Lee GW,Kim JY,Koh EH,Kang D,Choi DS,Maeng KY,Lee JS||Genetics and molecular research : GMR (11:4034)||2012|
Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype.
MA1-35720 was used in immunohistochemistry to study the correlation of epithelial-mesenchymal transition with triple negative phenotype and high histological grade in breast cancer
|Jeong H,Ryu YJ,An J,Lee Y,Kim A||Histopathology (60:E87)||2012|
Investigation of immunohistochemical ER¿, ERß and ERßcx expressions in normal and neoplastic breast tissues.
MA1-35720 was used in immunohistochemistry to study the expression of ERalpha, ERbeta and ERbetacx in normal and neoplastic breast tissues
|Bozkurt KK,Kapucuo¿lu N||Pathology, research and practice (208:133)||2012|
Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
MA1-35720 was used in immunohistochemistry to investigate the correlation of COX-2 overexpression with HER-2/neu overexpression in invasive breast carcinomas
|Çiri¿ IM,Bozkurt KK,Ba¿pinar S,Kapucuo¿lu FN||Pathology, research and practice (207:182)||2011|
The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.
MA1-35720 was used in immunohistochemistry to evaluate a quantum dot-based nanotechnology for breast cancer prognosis
|Chen C,Xia HS,Gong YP,Peng J,Peng CW,Hu MB,Zhu XB,Pang DW,Sun SR,Li Y||Biomaterials (31:8818)||2010|
Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone.
MA1-35720 was used in immunohistochemistry to study the relationship between bone tumors and lung nodules
|Alberghini M,Kliskey K,Krenacs T,Picci P,Kindblom L,Forsyth R,Athanasou NA||Virchows Archiv : an international journal of pathology (456:97)||2010|
Dendritic cell sarcomas/tumours of the breast: report of two cases.
MA1-35720 was used in immunohistochemistry to report on two cases of dendritic cell sarcomas/tumours of the breast
|Kapucuoglu N,Percinel S,Ventura T,Lang R,Al-Daraji W,Eusebi V||Virchows Archiv : an international journal of pathology (454:333)||2009|
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
MA1-35720 was used in immunohistochemistry to study the prognostic features of basal-like breast tumors in a series of hormone receptor-negative invasive breast cancer tumors
|Liu H,Fan Q,Zhang Z,Li X,Yu H,Meng F||Human pathology (39:167)||2008|
Prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma.
MA1-35720 was used in immunohistochemistry to study the prognostic and predictive value of c-erbB2 overexpression in osteogenic sarcoma
|Rakesh Kumar V,Gupta N,Kakkar N,Sharma SC||Journal of cancer research and therapeutics (2:20)||2007|
Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
MA1-35720 was used in immunohistochemistry to study EGF receptor pathway activation in completely resected non-small cell lung cancer
|Volante M,Saviozzi S,Rapa I,Ceppi P,Cappia S,Calogero R,Novello S,Borasio P,Papotti M,Scagliotti GV||Cancer (110:1321)||2007|
Expression of c-kit proto-oncogene product in breast cancer tissues.
MA1-35720 was used in immunohistochemistry to study the expression of the c-kit proto-oncogene protein in benign and malignant breast tumors
|Ero¿lu A,Sari A||Medical oncology (Northwood, London, England) (24:169)||2007|
Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients.
MA1-35720 was used in immunohistochemistry to study the predictive value of tumor cell expression of HLA-DM in breast carcinoma patients
|Oldford SA,Robb JD,Codner D,Gadag V,Watson PH,Drover S||International immunology (18:1591)||2006|
Intraepidermal cells of Paget's carcinoma of the breast can be genetically different from those of the underlying carcinoma.
MA1-35720 was used in immunohistochemistry to study the genetic differences between intraepidermal cells of Paget's carcinoma and the underlying carcinoma
|Morandi L,Pession A,Marucci GL,Foschini MP,Pruneri G,Viale G,Eusebi V||Human pathology (34:1321)||2003|
erbB-2 (HER-2) and breast cancer progression.
MA1-35720 was used in immunohistochemistry to study HER2 expression in breast cancer primary tumors and metastases
|Edgerton SM,Moore D,Merkel D,Thor AD||Applied immunohistochemistry and molecular morphology : AIMM (11:214)||2003|
Toker cells are probably precursors of Paget cell carcinoma: a morphological and ultrastructural description.
MA1-35720 was used in immunohistochemistry to study Toker cells as likely precursors of Paget cell carcinoma
|Marucci G,Betts CM,Golouh R,Peterse JL,Foschini MP,Eusebi V||Virchows Archiv : an international journal of pathology (441:117)||2002|
Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.
MA1-35720 was used in immunohistochemistry to investigate the expression of erbB-4/HER-4 GFR isoforms and its role in ovarian cancer
|Gilmour LM,Macleod KG,McCaig A,Gullick WJ,Smyth JF,Langdon SP||Cancer research (61:2169)||2001|
Epidermal growth factor receptor (EGFR) expression in childhood brain tumors.
MA1-35720 was used in immunocytochemistry to investigate the role of epidermal growth factor receptor (EGFR) expression in childhood brain tumors
|Bodey B,Kaiser HE,Siegel SE||In vivo (Athens, Greece) (19:931)||2005|